Clinical Trials Logo

Clinical Trial Summary

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04883905
Study type Observational
Source Alnylam Pharmaceuticals
Contact Alnylam Clinical Trial Information Line
Phone 1-877-ALNYLAM
Email clinicaltrials@alnylam.com
Status Recruiting
Phase
Start date April 26, 2021
Completion date April 2027

See also
  Status Clinical Trial Phase
Completed NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Phase 3
Terminated NCT03547297 - INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Not yet recruiting NCT04923516 - Prevalence of Acute Hepatic Porphyria
Recruiting NCT05344599 - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed NCT02240784 - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Approved for marketing NCT04056481 - Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria